Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 2

Conditions

Ovarian Neoplasms 104Breast Neoplasms 76Fallopian Tube Neoplasms 47Multiple Myeloma 32Carcinoma, Ovarian Epithelial 27Neoplasms 23Lymphoma 16Sarcoma 13Triple Negative Breast Neoplasms 12Recurrence 12Neoplasm Metastasis 12Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Non-Hodgkin 8Hodgkin Disease 8Neoplasms, Plasma Cell 6Prostatic Neoplasms 5Burkitt Lymphoma 5Solid Tumors 4Sarcoma, Kaposi 4Sarcoma, Ewing 4Pancreatic Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Leiomyosarcoma 4Endometrial Neoplasms 4Carcinoma 4Breast Neoplasms, Male 4Uterine Cervical Neoplasms 3Rhabdomyosarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Cyclophosphamide 32Etoposide 18romidepsin 17fludarabine 17Vincristine 17Doxorubicin 16Rituximab 14Prednisone 14Melphalan 14Gemcitabine 13Brentuximab Vedotin 13Lenalidomide 12Peripheral Blood Stem Cell Transplantation 11Cytarabine 11Whole-Body Irradiation 10Biopsy 1010-propargyl-10-deazaaminopterin 10pembrolizumab 9fludarabine phosphate 9Specimen Handling 9Busulfan 9Mycophenolic Acid 8Granulocyte Colony-Stimulating Factor 8Depsipeptides 8Carmustine 8Bortezomib 8duvelisib 7Vorinostat 7Methotrexate 7Magnetic Resonance Spectroscopy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × liposomal doxorubicin × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT01902225 2020-06-09

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

University of California, San Francisco

Phase 1 Completed
24 enrolled
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00161239 2009-12-11

LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma

Rutgers, The State University of New Jersey

Phase NA Terminated
64 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡